MACROH2A2

Across TCGA pan-cancer cohorts, MACROH2A2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MACROH2A2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MACROH2A2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MACROH2A2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where MACROH2A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MACROH2A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.211	<.001	12	view →
PDAC	Female	All	−0.823	<.001	8	view →
HNSC	Female	All	−0.587	.019	6	view →
LSCC	All	All	+0.154	<.001	4	view →
COAD	All	All	−0.141	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MACROH2A2–CCRCC

Open the CCRCC breakdown →